News Release - November 2, 2007

Gilead Announces 48-Week Data from Two Pivotal Phase III Studies Evaluating Viread(R) For the Treatment of Chronic Hepatitis B

Source: Gilead Sciences

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.